Category: Corona Virus

Page 401«..1020..400401402403..410420..»

The Seven Habits of COVID-Resilient Nations – The Atlantic

February 16, 2022

The tweet has stuck with me for months now: a chart of cumulative COVID-19 deaths per capita in the United States, the United Kingdom, and South Korea. The U.S. and U.K. lines rise up like mountains relative to the valley of South Korea below. Even as Omicron-related deaths have increased in South Korea more recently, the picture hasnt changed much.

South Korea kept deaths 40 times lower all the way till 75% of population fully vaccinated, the physician Vincent Rajkumar marveled on Twitter in response to the chart. This is success.

A more apt word than success might be resilience. As I have previously argued, the COVID crisis has underscored that clout in the 21st centuryan era rife with systemic threats including climate change, cyberattacks, and economic criseswill depend on a countrys ability to anticipate and absorb large-scale shocks, adapt to their disruptions, and rapidly bounce back (or even forward) from them. It will depend on resilient power. And through its response to the coronavirus so far, South Korea has emerged as a paragon of resilience governance.

South Korea hasnt proved to be the only resilient power in this period; other standouts include New Zealand and the Nordic countries. Yet South Korea is unusual in that it has not only repeatedly suppressed the spread of the virus and kept deaths to relatively low levels, but also never instituted a full lockdown. As a result, it has experienced much less economic fallout from the crisis than most other major economies. In contrast to other countries that excelled at one stage of the pandemic but struggled at others, South Korea has somehow respectably navigated every stage. After a sluggish start to its vaccine campaign, it now has one of the worlds highest vaccination rates. South Korea has also amassed soft power and diplomatic influence by providing pandemic-related assistance to other countries and establishing itself as a widely perceived model for how democracies should contend with COVID-19.

Uri Friedman: The pandemic is revealing a new form of national power

How did South Korea escape the pandemic relatively unaffected economically, with deaths at such low levels, while now vaccinating at such a high level that it has protected itself from future waves of illness and harsh lockdowns? the public-health expert Devi Sridhar recently inquired. Thats the question we should all be asking.

Below is my answer to that questionin the form of the broad lessons that other countries should learn from South Koreas achievements. These are the seven habits of highly resilient nations.

In 2015, an outbreak of Middle East respiratory syndrome (MERS), also caused by a coronavirus, tore through South Koreas hospitals and caught the government off guard. After initially failing to provide sufficient testing and transparent information about the crisis, however, officials eventually got the outbreak under control.

This history of lived resilience, as Michele Grossman, a resilience expert at Deakin University in Melbourne, Australia, once described it to me, gave the South Korean government and public confidence from the start of the SARS-CoV-2 outbreak, when others were either panicking or complacent, that they could prevent the virus from spiraling out of control. This might seem like an encouraging lesson: If resilience is born of the sort of trauma every country has experienced during this pandemic, then every country should now theoretically be primed to be more resilient in the future.

Adversity is not a sufficient condition for resilience, however. As The Atlantics Derek Thompson has written, what has set the South Korean government and people apart is their willingness to learn from that adversity and adapt their practices, policies, and institutions accordingly. South Koreas playbook for containing COVID-19rapid and widely accessible testing, sophisticated contact-tracing technology, and treatment measures such as compulsory isolation of serious casessprang from new legislation and government infrastructure developed as a direct result of MERS and other prior epidemics, such as a 2009 outbreak of H1N1 influenza.

As part of its dozens of post-MERS reforms, the government enhanced its data-collection methods and medical and laboratory facilities. It empowered the Korea Disease Control and Prevention Agency (KCDA). It identified high-priority infectious diseases, stockpiled personal protective equipment and other medical essentials, crafted a plan to disseminate supplies across the country, and conducted drills. MERS also prompted the government to develop closer relationships with biotechnology companies, which paid dividends when the novel coronavirus hit, enabling the country to quickly acquire reagents for diagnostic tests.

A December study by Bertelsmann Stiftung, which examined 29 countries in the European Union and the Organization for Economic Cooperation and Development, found that from the earliest days of the coronavirus outbreak, South Korea based its public-health interventions on scientific and socioeconomic expertise from a range of government entities. More broadly, according to the German foundation, countries that can speedily and successfully integrate expert advice into new policies, or adjust existing policies, tend to respond better to crises.

Uri Friedman: The dueling ideas that will define the 21st century

South Koreas overall COVID strategy was shaped by deference to such expertise. As Sridhar, the public-health expert, has argued, the countrys short-term focus on maximum suppression helped buy time for scientists to find a sustainable exit from the crisis through the development and approval of vaccines in 2020 and therapeutics in 2021.

Resilience depends on governments responding early and decisively to fluid realities. That, in turn, requires a commitment to Follow the data as a beacon for policy and decision making, Grossman, of Deakin University, told me.

South Korea has advanced data infrastructureincluding a cutting-edge (if also problematic, from a privacy perspective) contact-tracing systemthat enabled authorities to swiftly collect and analyze various sorts of pandemic-related data as a means of detecting early warning signs and assessing the effects of government policies. Employing its sensitive, multilevel alert system for infectious-disease risks, the government shifted its focus to economic recovery when new COVID cases dropped and shifted back to virus mitigation when cases surged again.

South Korea was one of only several countries in the Bertelsmann Stiftung study that succeeded in regularly reviewing the effectiveness of their policies, and in adapting them on an ongoing basis to rapidly changing circumstances or new knowledge, the report notes.

That achievement should not be underestimated. Real-time learning [during a crisis] is very, very difficult in the majority of countries, including nearly all of the studys front-runners, Christof Schiller, a governance expert at Bertelsmann Stiftung and a co-author of its report, told me. Korea could be an exception there.

New Zealand has been the worlds brightest star for crisis communications during the pandemic (its prime minister actually has a degree in communications), but South Korea has distinguished itself in this domain as well, consistently conveying a coherent containment strategy to its people.

As early as January 30, 2020, when the country had only five confirmed COVID cases, the government initiated twice-daily press briefings with public-health officials. It quickly issued press releases and web resources packed with data on the state of the outbreak and steps to counteract it, deployed a mobile-friendly emergency-alert system, established a 24-hour COVID hotline, and disseminated infographics on measures to avoid infection.

Here, too, the South Korean governments adherence to learning was key. The countrys Infectious Disease Control and Prevention Act, shaped by lessons from the H1N1 and MERS outbreaks, afforded the public a right to be informed about disease outbreaks and about government responses to them, note Thomas Kalinowski and Sang-young Rhyu, Bertelsmann Stiftungs South Korea experts. They explain that as a result, the government largely disclosed its actions and plans, and was transparent even about difficulties that threatened to increase public levels of frustration, such as the mask shortages in the early days of the coronavirus outbreak. In leveling with the public about these challenges, the government restored civic trust and encouraged the population to engage in a communal effort to prevent the spread of the virus.

That transparency also helped mobilize the private sector to boost South Koreas resilience by, for instance, developing mobile apps and websites that draw on government data to track mask inventories in stores or paths of viral transmission.

Writing for The Atlantic in 2020, the political scientist Francis Fukuyama argued that the most significant factor in national performance against the pandemic was whether citizens trust their leaders, and whether those leaders preside over a competent and effective state. Other scholars have since similarly discovered correlations between countries resilience to COVID-19 and their levels of trust in government and within society.

Read: Whats really behind global vaccine hesitancy

The authors of one such study of 177 countries and territories recently estimated that if the citizens of every country trusted one another at the level evident in South Korea, which ranked in the 75th percentile for this metric in their survey, the first 21 months of the global coronavirus outbreak might have produced 40 percent fewer infections.

South Korea is not a paragon of public trust in government. Nevertheless, the South Korean public has generally been willing to follow the governments pandemic guidelines, perhaps because the countrys COVID-19 response has been largely expert-led and depoliticized. In the global survey on trust that it released last month, the public-relations firm Edelman found that South Koreans trust in scientists (70 percent) and national-health authorities (56 percent) remained high relative to trust in government leaders (35 percent). Koreans also tend to be more trusting of their civil service, which has a strong culture of performance and accountability assessments, than they are of appointed or elected officials.

The Bertelsmann Stiftung study notes that South Korea was one of several more centralized countries that topped their rankings in part because national coordination efforts proved sensitive to local concerns and were thus carried out with the least friction, by through local authorities empowered to find solutions that work at the local level.

By leveraging a centralized but flexible system, the government was able to establish regional centers for disease control and prevention and rush resources, health-care workers, and public-health officials to areas reeling from surges in cases. The governments Central Disaster and Safety Countermeasures Headquartersled by the prime minister and established in February 2020held daily high-level meetings during acute periods of the pandemic to coordinate disaster response across central-government ministries and 17 provinces and major cities.

Notably, many of the countries that have proved most resilient against COVID-19 have been small nations such as New Zealand and the Nordic countries or midsize ones such as South Korea. Maybe this elaborate interplay between national and local systems is easier to pull off in such countries than in larger, more complex, and more diverse ones like the United States. A study of 116 national responses to the pandemic by the Lowy Institute in Australia last year found that countries with populations of fewer than 10 million people proved more agile than the majority of their larger counterparts. Its just one example of how traditional measures of national powermilitary spending, population size, gross domestic productdont necessarily translate into resilience.

South Koreas commitment to continuous learning, scientific expertise, and following the data extended not just to assessments of its own performance during the pandemic but also to assimilating insights from other countries grappling with the same challenges.

Resilient countries dont go it alone, Grossman explained; instead, they navigate toward and share resources; understand that their own well-being is interdependent with, and contingent upon, the well-being of the rest of the world; and act to reinforce the reciprocal relations that underwrite this recognition.

South Korea has not been perfect on this score. Kalinowski and Rhyu write that the government has remained inward-looking during the pandemic, showing a willingness to promote South Koreas successes against COVID-19 to the world but less interest in coordinating actions with international partners.

Nevertheless, the government has established travel bubbles with nearby countries and shared its COVID-19 knowledge, testing kits, and anonymized patient data with other countries and international organizations, while launching the Group of Friends of Solidarity for Global Health Security at the United Nations as a platform for countries to exchange lessons from their responses to the virus and other public-health challenges.

Derek Thompson: How Denmark decided COVID isnt a critical threat to society

The specific factors that have enabled South Korea to be resilient to COVID-19its post-MERS crisis-management system, for instancemay not help it respond resiliently to other systemic threats; South Korea performed less well on Bertelsmann Stiftungs assessments of economic, welfare-state, and democratic resilience during the coronavirus crisis.

Now that the Omicron variant is generating a substantial wave of new COVID cases in South Korea, this might also seem like an odd time to be singling out the country as a model. But the government is once again adapting, for example by ditching its celebrated pandemic playbook for a new one that focuses resources on the most at-risk COVID patients.

And, crucially, resilience is not the absence of failure. It is, instead, failure with grace, followed by robust recovery. For two years weve sought out neat success stories in the struggle with COVID. The real trick is managing vulnerabilities to avoid surrendering to shock.

Read the original post:

The Seven Habits of COVID-Resilient Nations - The Atlantic

Coronavirus Omicron variant, vaccine, and case numbers in the United States: Feb. 15, 2022 – Medical Economics

February 16, 2022

Total vaccine doses distributed: 676,650,925

Patients who've received the first dose: 252,144,326

Patients whove received the second dose: 213,962,983

% of population fully vaccinated: 64.4%

% of infections tied to the Omicron Variant: 100%

View post:

Coronavirus Omicron variant, vaccine, and case numbers in the United States: Feb. 15, 2022 - Medical Economics

COVID-19: New combination of antivirals may be an effective treatment – Medical News Today

February 16, 2022

After almost 2 years, the COVID-19 pandemic continues to be an issue around the world. To date, there have been more than 414 million confirmed cases worldwide, and the illness has caused more than 5.8 million deaths.

There are currently a number of different drugs at different stages of research evaluation to test their effectiveness against SARS-CoV-2, the virus that causes COVID-19.

Part of these efforts is a research group from the University of Pennsylvania that has identified a combination of antiviral drugs to treat COVID-19. The blend includes an experimental drug called brequinar with the drugs remdesivir or molnupiravir.

Thus far, researchers have tested this combination on both human respiratory cells and in mice. They believe the results they have seen show the drug combination has the potential to become a promising treatment for COVID-19.

The results from this study appear in the scientific journal Nature.

As the name suggests, an antiviral drug combats viruses that get into the human body. Antiviral drugs can enter cells infected with a virus and make it harder for the virus to bind with those cells. Additionally, some antiviral drugs can stop a virus from genetically replicating itself. Antiviral drugs also boost the bodys natural immune system, giving it an edge in fighting off a viral infection.

Because the SARS-CoV-2 virus causes COVID-19, there are currently a number of ongoing research studies around the use of different antiviral drugs to combat the disease.

For example, a new study found a combination of two specific antivirals may help fight off SARS-CoV-2 infection. Pharmaceutical company Pfizer also released data for a new antiviral medication that received approval for use in the United Kingdom in October 2021.

In October 2020, the Food and Drug Administration (FDA) approved the antiviral drug remdesivir as the first treatment for COVID-19 for adults and children over the age of 12. The FDA originally granted an emergency use authorization (EUA) for the drug in May 2020.

Results from three clinical trials found people hospitalized with COVID-19 who received remdesivir had higher rates of symptom improvement compared with receiving a placebo or only standard of care. In January 2022, the FDA expanded the use of remdesivir to certain nonhospitalized people with COVID-19 to treat mild-to-moderate symptoms.

Remdesivir is one of the potential drug candidates researchers from the University of Pennsylvania found during their initial screening of about 18,000 drugs.

Researchers examined the drugs for antiviral activity against live SARS-CoV-2 virus inside human epithelial respiratory cells. Using this method, scientists narrowed the field down to 122 drugs that showed antiviral activity and selectivity against SARS-CoV-2.

According to principal investigator Dr. Sara Cherry, professor of pathology and laboratory medicine and director of the program for chemogenomic discovery at the University of Pennsylvania, the goal was to identify drugs with antiviral activity against SARS-CoV-2 that are active in respiratory cells. We identified a number of drugs, including a group of nucleoside analogs, which are the largest group of approved antivirals, Dr. Cherry told MNT.

Importantly, we identified the two drugs approved for COVID-19 remdesivir and molnupiravir, which is under EUA.

A nucleoside analog is a type of antiviral drug that imitates a humans natural nucleoside. A nucleoside is an organic molecule in the body comprised of a nitrogenous base and sugar. When used to deliver an antiviral medication, a nucleoside analog enters the body and is able to enter cells where there is a virus. Certain compounds within the nucleoside analog activate, causing it to become a nucleotide. Nucleotides are building blocks of the bodys genetic DNA and RNA code.

Finding nucleoside analogs, which are mimics of our nucleosides and inhibitors of our enzymes that make nucleosides, led us to the hypothesis that the combination may be more than the sum of their parts, [which] is synergistic, Dr. Cherry explained. Synergy is difficult to find, and our discovery may lead to the use of these combinations in treatments.

Additionally, Dr. Cherry said the researchers found a number of other drugs that fall into diverse classes, including drugs that inhibit a humans nucleoside biosynthesis enzymes. The nucleoside biosynthesis inhibitor Dr. Cherry refers to is the experimental drug brequinar.

According to the study, a nucleoside biosynthesis inhibitor like brequinar stops the body from producing nucleosides. This made sense because the [SARS-CoV-2] virus uses the nucleoside building blocks created by our cells to produce the viral RNA, she added. Ultimately, brequinar helps prevent the SARS-CoV-2 virus from spreading in a persons body through the use of their RNA.

Once Dr. Cherry and her team identified the antiviral drug combination they felt would be most effective brequinar plus remdesivir or molnupiravir they tested the mix on both plated human epithelial lung cells and in mice.

Within both models, scientists observed the drug combination of a nucleoside biosynthesis inhibitor with a nucleoside analog led to a significant reduction in viral replication of the SARS-CoV-2 virus.

The research team also found adding an additional antiviral called Paxlovid to the mix could provide an extra boost against the SARS-CoV-2 virus. The FDA approved Paxlovid in December 2021 as the first oral treatment for mild-to-moderate COVID-19 in children and adults over the age of 12 at a high risk of developing severe illness.

For this study, the research team focused on testing these antiviral drug combinations in cells from a humans lower respiratory tract, such as the lungs.

We found that the combination is active in a respiratory cell line, as well as in air-liquid interface cultures derived from the nasal epithelium [and] from bronchial cells, Dr. Cherry said when asked if she felt this drug therapy would also be effective in the upper respiratory tract. Therefore, we think that this will be active in the upper respiratory tract in humans.

Dr. Cherry also believes this antiviral drug combination could potentially be effective against new variants of SARS-CoV-2. Given that these drugs target RNA replication of the virus, which does not evolve rapidly, and not the Spike protein, it is likely that this combination will be active against emerging variants, she explained. Indeed, we found that the combination showed synergy against all of the variants we tested. And we are currently testing Omicron.

As for the next steps for this research, Dr. Cherry said they are currently continuing to explore the use of these drug combinations, as well as other drugs the research team identified in the screening to determine how they impact SARS-CoV-2 and if they could treat COVID-19.

Researchers also mentioned that the next step in testing these drug combinations would include testing in clinical trials.

That is of interest to Dr. Fady Youssef, a board certified pulmonologist, internist, and critical care specialist at MemorialCare Long Beach Medical Center. Dr. Youssef spoke to MNT about this study and said it is encouraging to see possibilities within combinations of these antiviral drugs.

The biggest question we have is how to identify and treat patients early in their disease state before the virus progresses and causes pneumonia, he explained. Many of the interventions we have dont perform as well when the disease has progressed, including antivirals. The most opportune time to quell a fire is the earliest time you can.

Another big question, Dr. Youssef continued, is going to be: How does this perform when applied in [humans]? This is a good precursor that theres a signal there thats worth testing. How its going to perform in [humans] is unknown and how much activity its going to have in the upper respiratory tract versus lower tract is going to depend on how it performs in human trials.

For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.

Here is the original post:

COVID-19: New combination of antivirals may be an effective treatment - Medical News Today

COVID-19: Wales becomes first UK nation to offer coronavirus vaccines to all five to 11-year-olds – Sky News

February 16, 2022

Wales has become the first UK nation to announce it will offer COVID-19 vaccines to all five to 11-year-olds.

Health minister Eluned Morgan said she has received the "yet to be published" final advice from the Joint Committee for Vaccination and Immunisation (JCVI) on COVID-19 jabs for children aged five to 11 who are not judged to be at clinical risk.

"I have accepted this advice and thank the JCVI for scrutinising the science and evidence and setting out its advice in a careful and considered way," Baroness Morgan said.

Please use Chrome browser for a more accessible video player

"Our intention, as it has been from the start of the pandemic, is to follow the clinical and scientific evidence."

She said the full JCVI advice would be published in "due course".

Delay to JCVI announcement 'perplexing'

There has been a delay to the official announcement, reportedly because of disagreements between the UK government and the JCVI - with an announcement expected on 21 February.

Facing questions in a Plenary session at the Senedd, Baroness Morgan said the delay was a "shame" and "perplexing".

"In relation to vaccination of children, the JCVI has yet to publish its report, although there are lots of clues in The Guardian and other places where there seems to have been lots of leaks come out," she said.

"It's a shame and it's perplexing to understand why that has not been published yet.

"But I have seen a copy of that advice and we will be commencing the rollout of vaccinations for five to 11-year-olds."

Subscribe to the Daily podcast on Apple Podcasts, Google Podcasts, Spotify, Spreaker

'Very difficult decision'

Baroness Morgan did not lay out a timetable for when this would happen, saying: "We're not going to do that as a matter of urgency, as we did over the Christmas period. That's partly because the risk isn't as great to that cohort.

"And we're also waiting to hear from the JCVI to see whether they'll need a booster on top of the booster for older age groups in the spring."

She added: "Of course, it's likely to have been a very difficult decision for the JCVI, because generally, children have a milder illness and fewer hospitalisations.

"But, of course, they have to balance that against the prospect of missing school.

"We have to consider very different issues when it comes to the vaccination of children as young as five years old, of course, so we'll be in a position where we will expect those children to be accompanied by an adult.

"There will be a need for informed consent, but there will be an opportunity for siblings, for example, to be brought at the same time."

'No decisions' made by Westminster government

In December, the JCVI updated its guidance to suggest that children aged five to 11 who are in a clinical risk group or who are a household contact of someone who is immunosuppressed should be offered a primary course of vaccination.

At that time, the vaccine experts said further advice regarding jabs for healthy five to 11-year-olds would be issued in due course "following consideration of additional data relevant to this age group and on the Omicron variant more broadly".

The government in England is expected to make an announcement on jabs for all five to 11-year-olds next week.

"No decisions have been made by ministers on the universal offer of a COVID-19 vaccine to all five to 11-year-olds," a spokesperson said.

"We are committed to reviewing the JCVI's advice as part of wider decision-making ahead of the publication of our long-term strategy for living with COVID-19."

Link:

COVID-19: Wales becomes first UK nation to offer coronavirus vaccines to all five to 11-year-olds - Sky News

Coronavirus news, more storms brewing: Whats trending today – cleveland.com

February 16, 2022

A look at some of the top headlines trending online today around the world including the latest on another round of winter storms, tensions with Russia, coronavirus developments and much more.

Russia says some troops returning to bases from near Ukraine amid invasion fears (NBC)

Russia-Ukraine standoff: What you need to know now (CBS)

New storm to bring possible severe weather toward South, Midwest (ABC)

Trump Organizations accounting firm says 10 years of financial statements are unreliable (CNN)

Wholesale prices likely surged again in January as inflation accelerates (Fox)

BA.2 Stealth Variant Found in Nearly All U.S. States as Reinfection Capability Unclear (Newsweek)

Vaccine scientists have been chasing variants. Now, theyre seeking a universal coronavirus vaccine (Washington Post)

Amazon and Walmart lift mask rules for vaccinated workers (CBS)

Unvaccinated medical workers turn to religious exemptions (AP)

Canadas Trudeau invokes emergency powers in bid to end protests (Reuters)

Six months of Taliban: Afghans safer, poorer, less hopeful (AP)

Bridgerton Season 2 Trailer Released by Netflix (Hollywood Reporter)

Elon Musk Gave $5.7 Billion of Tesla Shares to Charity Last Year (WSJ)

Actor who faked movie deals sentenced to 20 years in prison for massive Ponzi scheme (LA Times)

See the original post:

Coronavirus news, more storms brewing: Whats trending today - cleveland.com

Coronavirus Briefing: How to ‘Live with’ Covid – The New York Times

February 13, 2022

For the first year of the pandemic, I routinely received questions from friends, family, patients and acquaintances about how to think about risk in different situations before making decisions, Eisenberg said. Now, hardly anyone asks those questions and most people have settled on their own conclusions about what works for them.

We recently asked readers: Are you ready to live with the virus? Its a hot topic: Nearly 3,000 of you wrote in. Thank you to everyone who shared their thoughts. If youd like to continue the conversation, you can tell us how you feel in the comments section here.

Its time to start living with Covid by normalizing it. Its a virus. It will keep mutating. Its never going to be over, no matter how long we make concessions. And if its never over, as a nation, we cant grieve, find closure, adapt and help each other and our kids find silver linings and hope. We need to begin the healing process. We need to allow the healthy to start living. Ariele Taylor, Bay Area, Calif.

If living with the virus means letting down my guard, then NO. Im not remotely ready. Im prepared to wear masks for the rest of my life, if need be. Im not going to get casual about Covid. Im 74. Im already dealing with fibromyalgia. I dont want long-Covid on top of that! For me, masking up when I go out is an inconvenience I can live with. Kathryn Janus, Chicago

Covid boosters. Data released by the Centers for Disease Control and Prevention showed that booster shots against the coronavirus lose much of their potency after about four months, adding to evidence suggesting that some Americans may need a fourth dose.

Vaccines for young children. The Food and Drug Administration said that it would wait for dataon the effectiveness of three doses of the Pfizer-BioNTech coronavirus vaccine in children younger than 5 before deciding whether to authorize the vaccine for that age group.

Yes, we need to stop dividing citizens over vaccination choice and vaccine passports for good. We havent been able to enjoy restaurants, festivals, museums or any kind of travel because of this requirement, due to different vaccine statuses in our family. I am sympathetic to the most vulnerable and immunocompromised, but unless the government can approve more viable treatments for Covid, they are not the only people fighting to survive this pandemic. We have exhausted teachers, business owners, restaurant staff, grocery store clerks, pharmacists, retail workers all bearing the brunt of restrictions that they need to enforce on an equally exhausted population. By living with the virus, we are equipped with knowing what to do if we get infected, we have new protocols to self-isolate, to wear masks, or even get vaccinated if one feels unsafe. Beyond that, there is not much more we can do as a person. Dahlia, Montreal

I am ready! I want to travel with my family, do my job in full capacity and have my child in school without a mask if they choose. It has been long enough and its time to let people start choosing which precautions they want to take. You can wear a mask for the rest of your life should you choose. No one will ever stop you from doing that. Stacy Foster, Portland, Ore.

Go here to see the original:

Coronavirus Briefing: How to 'Live with' Covid - The New York Times

Coronavirus (COVID-19) Update: FDA Postpones Advisory Committee Meeting to Discuss Request for Authorization of Pfizer-BioNTech COVID-19 Vaccine for…

February 13, 2022

For Immediate Release: February 11, 2022 Statement From: Janet Woodcock, M.D. Acting Commissioner of Food and Drugs - Food and Drug Administration

Peter Marks, M.D., PhD. Director - Center for Biologics Evaluation and Research (CBER)

The U.S. Food and Drug Administration has been notified by Pfizer that new data have recently emerged regarding its emergency use authorization request for the use of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age. As part of its rolling submission, the company recently notified the agency of additional findings from its ongoing clinical trial. Based on the agencys preliminary assessment, and to allow more time to evaluate additional data, we believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization.

Therefore, the FDA is postponing the Vaccines and Related Biological Products Advisory Committee meeting originally scheduled for Feb. 15. This will give the agency time to consider the additional data, allowing for a transparent public discussion as part of our usual scientific and regulatory processes for COVID-19 vaccines. We will provide an update on timing for the advisory committee meeting once we receive additional data on a third dose in this age group from the companys ongoing clinical trial and have an opportunity to complete an updated evaluation.

Since the early days of the pandemic, we have always followed the science in this ever-changing situation. Given the recent omicron surge and the notable increase in hospitalizations in the youngest children to their highest levels during the pandemic so far, we felt it was our responsibility as a public health agency to act with urgency and consider all available options, including requesting that the company provide us with initial data on two doses from its ongoing study. The goal was to understand if two doses would provide sufficient protection to move forward with authorizing the use of the vaccine in this age group. Our approach has always been to conduct a regulatory review thats responsive to the urgent public health needs created by the pandemic, while adhering to our rigorous standards for safety and effectiveness. Being able to begin evaluating initial data has been useful in our review of these vaccines, but at this time, we believe additional information regarding the ongoing evaluation of a third dose should be considered.

The agency will ensure the data support effectiveness and safety before authorizing a COVID-19 vaccine for use in our youngest children. In the meantime, the best way to protect children, including when they are at school or daycare, is to practice social distancing and masking in accordance with public health recommendations, and for their family members and caregivers to get vaccinated or receive a booster dose when eligible.

###

Boilerplate

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nations food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

02/11/2022

Read the original post:

Coronavirus (COVID-19) Update: FDA Postpones Advisory Committee Meeting to Discuss Request for Authorization of Pfizer-BioNTech COVID-19 Vaccine for...

Coronavirus FAQ: What’s the best way to protect school-age kids from COVID? – NPR

February 13, 2022

A child wears a KN95 mask for kids in Hastings-on-Hudson, New York. Tiffany Hagler-Geard/Bloomberg via Getty Images hide caption

A child wears a KN95 mask for kids in Hastings-on-Hudson, New York.

Each week, we answer frequently asked questions about life during the coronavirus crisis. If you have a question you'd like us to consider for a future post, email us at goatsandsoda@npr.org with the subject line "Weekly Coronavirus Questions." See an archive of our FAQs here.

Do kids really need masks if they've been vaccinated and had COVID?

Most kids who were either recently infected or vaccinated should have a strong enough immune response to protect them from getting COVID for several weeks or longer, says Dr. Abraar Karan, an infectious disease physician at Stanford University.

The combination of being vaccinated and having had COVID induces stronger immunity than just one or the other, he says in an email. "Of course, if they are immunocompromised, [the decision not to mask] will be more complicated and parents should consult with their physicians."

In general, though, recent infection and vaccination makes the risk of getting COVID so low that the extra benefit of a mask is negligible, says Seema Lakdawala, an associate professor at the University of Pittsburgh School of Medicine who specializes in respiratory viruses with pandemic potential.

That could change over the next year "if a new variant comes along that doesn't care very much about your recent omicron infection," says Dr. Emily Landon, an infectious disease specialist and chief hospital epidemiologist at University of Chicago Medicine.

But for now, if your vaccinated kid has recently recovered from COVID, the choice of whether to mask is up to you and your child, as long as you're not violating any mandates.

Many parents in this situation choose to keep masking their children "because it's part of the social contract of all of us trying to get through this together," Lakdawala says. If one kid stops wearing a mask to school, another may decide to opt out as well, she points out, since keeping track of everyone who got COVID and who is vaccinated is not feasible.

If you and your child decide to forgo masking, make sure your child is not pressuring classmates to take theirs off.

"If your kid is the only one not wearing a mask and they're trying to push other kids to not wear masks, even though it may be best for them to [mask]," she says, "that's not OK. So it's really important to talk with your kids in mask-optional settings about not trying to influence others and to be really tolerant of what they need."

So if I really don't want my elementary school-age kids to get COVID, what's the best way to protect them?

First, get your 5- to 12-year-old vaccinated, doctors and experts say. In a study published online Wednesday, scientists in Israel found that vaccinated children were half as likely to catch COVID as their unvaccinated peers. But this protection was short-term. After about five months, the rate of infection was almost the same for vaccinated and unvaccinated teenagers.

Even as case rates are plunging in some areas, multi-layered strategies are still necessary. Lakdawala compares the situation to a battlefield.

"If we're at war with the virus, the vaccine is our armor," she says. "That helps us from getting badly beaten. But it doesn't help us win, so we also need a mask as a shield that helps us block the virus, and then other ways to fight back like ventilation and ways to clean the air as a sword."

Parents should check whether their schools are up-to-date on their ventilation and air cleaning systems. That could include opening doors and windows at certain times of the day when classrooms are busiest, according to Lakdawala, and using portable air cleaners or a built-in air filtration system. Teachers wearing masks can also make a dent in classroom transmission. According to a study from Germany published in December, teachers wearing masks at school was a more effective strategy at reducing transmission of the virus than students wearing masks.

"Everyone wants kids to be in school and learning and interacting safely," Lakdawala says. "So we need to continue to think about all of the ways to reduce risk in all environments."

And what about masks for the kids?

Many experts have recommended upgrading to high-filtration respirators during the omicron surge. Indeed, these respirators (N95s, KN95s, KF94s) may be the only masks that are helpful against omicron.

N95 masks aren't available for children, but KN95 and KN94s are. Such masks could help kids in situations that call for added caution. If your kid's environment includes spending time with anyone at higher risk of complications from COVID, for example, keep that person in mind when making decisions about masking, advises Landon.

"If their best friend has Type 1 diabetes and has been battling some infections recently or has a primary immunodeficiency and has to take immunoglobulin infusions, then your kid should be [extra careful]," she says. "If your kid wants to keep being friends with that kid, they need to wear a mask all the time."

But for many families, KN95s or KN94s aren't a viable option. They are much more expensive than cloth or surgical masks and less reusable than cloth masks. On top of that, a child needs to wear the mask consistently to make it effective.

Sheila Mulrooney Eldred is a freelance health journalist in Minneapolis. She has written about COVID-19 for many publications, including The New York Times, Kaiser Health News, Medscape and The Washington Post. More at sheilaeldred.pressfolios.com. On Twitter: @milepostmedia.

View original post here:

Coronavirus FAQ: What's the best way to protect school-age kids from COVID? - NPR

Community Health Network, NAACP team up to offer COVID-19 vaccinations – WISHTV.com

February 13, 2022

INDIANAPOLIS (WISH) An American Legion post was bustling Saturday not just with veterans, but also with people giving and receiving COVID-19 vaccinations.

I always tell people, some shot, whether its through Moderna, Pfizer or the Johnson & Johnson, is better than no shot at all, said Tyjuan Garrett, second vice president of the Greater Indianapolis NAACP Branch No. 3053.

Garrett chose Tillman H. Harpole American Legion Post 249 on Dr. Martin Luther King Jr. Street for the vaccination site, which is central to where people who need public transportation could access the clinic.

What we are starting to notice is that when more people are taking the shot and more people have gotten vaccinated, and they have stories to tell, we notice the trepidation to taking the shot is decreasing. Theres still going to be those who are still skeptical, Garrett said.

Community Health Network provided shots for the flu and the coronavirus. Robin Ledyard, chief medical officer at Community Health, said, We know that 10% of people who get COVID tend to have long-lasting symptoms. We dont know if they are going to go away or not.

The NAACP, which hosted Saturdays four-hour clinic along with The Indianapolis Recorder, says it plans on having more vaccine clinics around Indianapolis soon.

Continue reading here:

Community Health Network, NAACP team up to offer COVID-19 vaccinations - WISHTV.com

Update on COVID-19 Protocols, Mask Requirement Limited to Instructional Spaces – COVID-19

February 13, 2022

Dear students, faculty, and staff,

Throughout the pandemic, we have continuously monitored a number of data and metrics, including university and local case counts, to assess the impact of COVID-19 on our campus and implement layered prevention strategies. Additionally, we have followed directives and guidance from public health officials to adjust our protocols as needed. We are extremely grateful to each of you for the part you have played in our response to COVID-19.

Status of COVID-19

We are certainly in a different place this spring than we were spring 2020 or even spring 2021. We have robust testing, and we have safe, effective, and widely available vaccines that reduce the severity of illness and the risk of hospitalization for those infected with the coronavirus. We have developed protocols that are proven to be effective when we experience a surge in cases. We have also seen our case counts reduce significantly from the beginning of the semester to today.

Updated Public Health Guidance

In accordance with recent communications from the Mississippi State Department of Health (MSDH), institutions of higher learning across the state have been granted the ability to modify mitigation strategies and to utilize CDC guidance to develop strategies for their own campus.

Based on the number of cases and positivity rates in our campus community, availability of health resources, and recommendations from health professionals, we are modifying our masking requirement.

Effective Monday, Feb. 14, 2022, the university will require face coverings only in instructional areas and healthcare settings, regardless of vaccination status.This includes classrooms and other academic spaces like laboratories as well as healthcare settings such as University Health Services.

Face coverings will not be required in other public spaces such as residence halls, libraries, dining facilities, the Student Union, Campus Recreation facilities, retail spaces, offices, conference rooms or extracurricular activities held in indoor on-campus spaces.

Supporting Community Members

We recognize that some individuals may be at higher risk, have a family member they are trying to protect, may not be up-to-date on their vaccines or not eligible, or feel more comfortable wearing a mask in indoor public spaces. We ask everyone to support and respect those in our community who need to, or choose to, wear a face covering in non-required spaces.

The university continues to support faculty and staff who wish to keep additional safeguards in work spaces, including plexiglass at desks/work stations. Faculty and staff may require face coverings for visits to their private offices, as well. Additionally, we will continue to provide face coverings to requesting departments.

Continued Monitoring of Community Impact

As we have done since the onset of the pandemic, we will continue to monitor the presence of the virus on our campus and adapt, if necessary, to uphold the health and safety of our community. We remain committed to making the necessary adjustments and adaptations to ensure that we meet our mission and serve our students. I appreciate all that you have done as a member of this campus community to contribute to that commitment.

Sincerely,

Glenn F. BoyceChancellor

Read more:

Update on COVID-19 Protocols, Mask Requirement Limited to Instructional Spaces - COVID-19

Page 401«..1020..400401402403..410420..»